News
March 14, 2025
Inductive Bio to Present at ACS Spring 2025 on the Future of AI in Drug Discovery
.svg)
The rapid rise of AI in drug discovery brings both unprecedented opportunities and complex challenges. From accelerating the development of better therapies to navigating the proliferation of tools and technologies, the path forward requires clarity, precision, and innovation. For small biotech companies, this moment also raises a critical question: how can we stay competitive with limited resources?
At ACS Spring 2025, our Co-founder & CEO Josh Haimson will explore these questions across two sessions that highlight the evolving role of AI in the discovery and development of new medicines.
Sunday, March 23
Unlocking a New Era: How AI is Transforming Drug Discovery and Development
A panel moderated by Maria-Jesus Blanco (Atavistik Bio)
- 10:45 AM – 11:30 AM PST
- Ballroom 20D, San Diego Convention Center
Monday, March 24
Competing with Goliaths: A Novel Pre-Competitive ADMET ML Consortium Accelerating Drug Discovery in Biotech Companies
- 4:35 PM – 5:00 PM PST
- Room 7B, San Diego Convention Center
These sessions will examine how AI is redefining medicinal chemistry, the value of pre-competitive ML consortium, and how biotechs can effectively adopt these tools to drive innovation.
Interested in meeting at ACS? Book time with us here.
- QC analytical reports (1H/13C/19F/2D NMR, chiral SFC)
- Propose, visualize, and triage forward and retrosyntheses
- Monitor the synthesis queue and flag stalled targets
- QC assay data as it lands and flag suspicious results
- Prioritize repeats and nominate compounds for downstream assays
- Analyze SAR and identify data gaps
- Evaluate IVIVC and suggest diagnostic experiments
- Design, enumerate, and triage analogs
- Launch and analyze physics-based workflows like docking and FEP
- Project human PK and efficacious dose
- Answer questions about a program’s history (what was learned and when)
- Track team progress against the target candidate profile
- Get new scientists up to speed on a program
- Make meeting-ready slides and figures
Prompt: I’m attaching two files with activity data, one with new data from today and one with historical data. Can you look through the new data and identify any QC issues that I should be aware of? Create a csv where every compound + assay run pair is labeled with any relevant issues.
Prompt: Do a nitrogen walk around the core of this molecule: O=C(NCC1=CC=C(C)C(F)=C1)C2=CC=C3C=C(N4[C@H](C)CCCC4)C=CN32
Prompt: Do an OH walk around this whole molecule: O=C(NCC1=CC=C(C)C(F)=C1)C2=CC=C3C=C(N4[C@H](C)CCCC4)C=CN32
Prompt: Replace the core of this molecule with this set of 5,6-ring systems (file attached): O=C(NCC1=CC=C(C)C(F)=C1)C2=CC=C3C=C(N4[C@H](C)CCCC4)C=CN32
[Related posts]
September 14, 2026
News
Inductive Bio launches Indy, an AI chemistry assistant, to double the capacity of every medicinal chemist
Indy is the world’s first medicinal chemistry agent. Indy outperforms Claude Opus 5 and GPT-5.6 Sol in head-to-head benchmarks that include QC’ing new assay data, analyzing SAR, and the design/triage of analogs.
June 30, 2026
News
Inductive Bio joins Anthropic’s Connector Ecosystem for Life Sciences, Surfacing State-of-the-Art ADMET Prediction to Drug Discovery Scientists through Claude
Inductive’s global ADMET prediction models are now available as a connector for Claude, enabling any drug discovery scientist working with Claude to access state-of-the-art predictive models directly in their existing workflow.
May 26, 2026
News
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery
New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to make lead-optimization-quality decisions starting in hit identification
December 8, 2025
News
Inductive Bio Announces an up to $21M Award to Develop AI Drug Toxicity Models that Improve Drug Safety Assessment with Leading Academic and Biopharmaceutical Organizations
Team to develop and validate computational models trained on data from organoids and advanced human model systems that will improve drug safety and reduce reliance on animal testing
August 20, 2025
News
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Partner to Deploy AI-driven Lab-in-the-loop Workflows Across the Biopharma Industry
This new partnership will streamline drug discovery with AI, faster ADME profiling, and automated compound management, helping scientists design better treatments with fewer resources.
May 8, 2025
News
Inductive Bio Raises $25M Series A to Transform Small Molecule Drug Discovery with Industry-Wide AI Platform
Funding will accelerate company’s work to democratize state-of-the-art AI models trained on a pre-competitive dataset to speed the successful development of life-saving therapies
September 29, 2024
News
Inductive Bio Announces Publication of Successful Drug Optimization Collaboration with Nested Therapeutics
Inductive Bio, a leader in leveraging machine learning (ML) to accelerate compound optimization for small molecule drug discovery, announces the publication of the approach and findings from their recent collaboration with Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers.
August 9, 2024
News
Inductive Bio to Host Panel on AI and ML in Drug Discovery at ACS Fall 2024
As artificial intelligence and machine learning continue to reshape the landscape of drug discovery, this panel will tackle one of the field’s most pressing questions: how do we separate real innovation from overpromised potential?
December 13, 2023
News
Inductive Bio Emerges from Stealth, Unveiling an ML Platform to Accelerate Compound Optimization in Drug Discovery
Inductive Bio emerged with $4.3M in a seed funding round co-led by a16z Bio + Health and Lux Capital, with participation from Character, Bessemer Venture Partners, Alleycorp, and others. Inductive's team has deep expertise building innovative ML products and bringing drugs into the clinic.